These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 26988771)
1. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC. Biswas T; Efird JT; Prasad S; James SE; Walker PR; Zagar TM Clin Breast Cancer; 2016 Jun; 16(3):212-6. PubMed ID: 26988771 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages? Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691 [TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: An institutional analysis. Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK Indian J Cancer; 2014; 51(2):163-6. PubMed ID: 25104201 [TBL] [Abstract][Full Text] [Related]
4. [Safety of breast-conserving treatment for triple-negative breast cancer]. Wang L; Ouyang T; Wang T; Xie Y; Fan Z; Fan T; Li J Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):947-52. PubMed ID: 26850668 [TBL] [Abstract][Full Text] [Related]
5. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644 [TBL] [Abstract][Full Text] [Related]
6. Inflammatory breast cancer: a single centre analysis. Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN Asian Pac J Cancer Prev; 2014; 15(7):3207-10. PubMed ID: 24815472 [TBL] [Abstract][Full Text] [Related]
7. [Comparative study of inflammatory and non-inflammatory locally advanced breast cancer - the experience of a Moroccan hospital]. Benbrahim Z; Berrada A; Amaadour L; Zahra El M'rabet F; Elfatemi H; Elfakir S; Mellas N; Arifi S Gynecol Obstet Fertil Senol; 2017 Nov; 45(11):604-608. PubMed ID: 29100820 [TBL] [Abstract][Full Text] [Related]
8. An institutional analysis of clinicopathological features of triple negative breast cancer. Sharma D; Singh G Indian J Cancer; 2016; 53(4):566-568. PubMed ID: 28485352 [TBL] [Abstract][Full Text] [Related]
9. Triple Negative Breast Cancer: 10-Year Survival Update of The Applied Treatment Strategy in Kuwait. Fayaz S; Demian GA; El-Sherify M; Eissa H; Aziz M; Abuzallouf S Gulf J Oncolog; 2019 Jan; 1(29):53-59. PubMed ID: 30957764 [TBL] [Abstract][Full Text] [Related]
10. Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy. Kim S; Park HS; Kim JY; Ryu J; Park S; Kim SI Yonsei Med J; 2016 Sep; 57(5):1192-8. PubMed ID: 27401651 [TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India. ; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553 [TBL] [Abstract][Full Text] [Related]
13. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Lacerda L; Reddy JP; Liu D; Larson R; Li L; Masuda H; Brewer T; Debeb BG; Xu W; Hortobágyi GN; Buchholz TA; Ueno NT; Woodward WA Stem Cells Transl Med; 2014 Jul; 3(7):849-56. PubMed ID: 24833589 [TBL] [Abstract][Full Text] [Related]
14. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast. Chen HL; Ding A Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199 [TBL] [Abstract][Full Text] [Related]
15. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Masuda H; Baggerly KA; Wang Y; Iwamoto T; Brewer T; Pusztai L; Kai K; Kogawa T; Finetti P; Birnbaum D; Dirix L; Woodward WA; Reuben JM; Krishnamurthy S; Symmans W; Van Laere SJ; Bertucci F; Hortobagyi GN; Ueno NT Breast Cancer Res; 2013 Nov; 15(6):R112. PubMed ID: 24274653 [TBL] [Abstract][Full Text] [Related]
16. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]. Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072 [TBL] [Abstract][Full Text] [Related]
17. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. Tung N; Gaughan E; Hacker MR; Lee LJ; Alexander B; Poles E; Schnitt SJ; Garber JE Breast Cancer Res Treat; 2014 Jul; 146(1):175-82. PubMed ID: 24839033 [TBL] [Abstract][Full Text] [Related]
18. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142 [TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer. Joyce DP; Murphy D; Lowery AJ; Curran C; Barry K; Malone C; McLaughlin R; Kerin MJ Surgeon; 2017 Oct; 15(5):272-277. PubMed ID: 28277293 [TBL] [Abstract][Full Text] [Related]
20. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy. Saigal K; Hurley J; Takita C; Reis IM; Zhao W; Rodgers SE; Wright JL Clin Breast Cancer; 2013 Oct; 13(5):335-43. PubMed ID: 23850216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]